INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,034,153 | +15.8% | 109,717 | -30.9% | 0.00% | 0.0% |
| Q2 2023 | $1,757,191 | -60.8% | 158,878 | -52.5% | 0.00% | 0.0% |
| Q1 2023 | $4,487,890 | +30.6% | 334,169 | +20.3% | 0.00% | 0.0% |
| Q4 2022 | $3,435,248 | +51.9% | 277,708 | +71.3% | 0.00% | 0.0% |
| Q3 2022 | $2,262,000 | +1.1% | 162,135 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $2,237,000 | -22.7% | 161,920 | -9.0% | 0.00% | 0.0% |
| Q1 2022 | $2,894,000 | +171.7% | 177,860 | +172.3% | 0.00% | – |
| Q4 2021 | $1,065,000 | +2.1% | 65,319 | -7.0% | 0.00% | – |
| Q3 2021 | $1,043,000 | -72.0% | 70,211 | -62.4% | 0.00% | -100.0% |
| Q2 2021 | $3,727,000 | -8.8% | 186,593 | +5.4% | 0.00% | 0.0% |
| Q1 2021 | $4,087,000 | -18.4% | 177,040 | -12.7% | 0.00% | -50.0% |
| Q4 2020 | $5,007,000 | -39.9% | 202,701 | +0.8% | 0.00% | -50.0% |
| Q3 2020 | $8,337,000 | -14.7% | 201,070 | -1.4% | 0.00% | -20.0% |
| Q2 2020 | $9,769,000 | -7.5% | 203,903 | +21.5% | 0.01% | -16.7% |
| Q1 2020 | $10,566,000 | -48.0% | 167,817 | +2.4% | 0.01% | -45.5% |
| Q4 2019 | $20,300,000 | +90.4% | 163,811 | +1.9% | 0.01% | +83.3% |
| Q3 2019 | $10,664,000 | -10.9% | 160,686 | +6.8% | 0.01% | -14.3% |
| Q2 2019 | $11,967,000 | -19.4% | 150,385 | +13.3% | 0.01% | -30.0% |
| Q1 2019 | $14,853,000 | +22.3% | 132,776 | +10.2% | 0.01% | +11.1% |
| Q4 2018 | $12,142,000 | -20.5% | 120,459 | -0.3% | 0.01% | -10.0% |
| Q3 2018 | $15,267,000 | +64.2% | 120,820 | +9.0% | 0.01% | +42.9% |
| Q2 2018 | $9,298,000 | +178.6% | 110,805 | +104.3% | 0.01% | +133.3% |
| Q1 2018 | $3,338,000 | +24.8% | 54,249 | +18.5% | 0.00% | +50.0% |
| Q4 2017 | $2,675,000 | -5.0% | 45,778 | -5.7% | 0.00% | 0.0% |
| Q3 2017 | $2,817,000 | -62.6% | 48,529 | -21.9% | 0.00% | -71.4% |
| Q2 2017 | $7,528,000 | +3.5% | 62,172 | -3.3% | 0.01% | 0.0% |
| Q1 2017 | $7,273,000 | +13.6% | 64,303 | +9.1% | 0.01% | 0.0% |
| Q4 2016 | $6,405,000 | -35.5% | 58,948 | -2.3% | 0.01% | -41.7% |
| Q3 2016 | $9,931,000 | +23.3% | 60,332 | +6.9% | 0.01% | +20.0% |
| Q2 2016 | $8,052,000 | +32.5% | 56,429 | +19.3% | 0.01% | +25.0% |
| Q1 2016 | $6,079,000 | -21.8% | 47,317 | -9.1% | 0.01% | -20.0% |
| Q4 2015 | $7,775,000 | -0.9% | 52,058 | +10.1% | 0.01% | -16.7% |
| Q3 2015 | $7,843,000 | -5.2% | 47,282 | +37.9% | 0.01% | +9.1% |
| Q2 2015 | $8,275,000 | +1.6% | 34,282 | +18.7% | 0.01% | 0.0% |
| Q1 2015 | $8,143,000 | +109.1% | 28,871 | +15.7% | 0.01% | +83.3% |
| Q4 2014 | $3,895,000 | -28.6% | 24,962 | +8.3% | 0.01% | -33.3% |
| Q3 2014 | $5,457,000 | +36.6% | 23,052 | +36.6% | 0.01% | +28.6% |
| Q2 2014 | $3,995,000 | -54.3% | 16,879 | -36.3% | 0.01% | -56.2% |
| Q1 2014 | $8,740,000 | +486.6% | 26,499 | +21.5% | 0.02% | +433.3% |
| Q4 2013 | $1,490,000 | +0.7% | 21,810 | +13.2% | 0.00% | 0.0% |
| Q3 2013 | $1,480,000 | +92.0% | 19,264 | +9.8% | 0.00% | +50.0% |
| Q2 2013 | $771,000 | – | 17,551 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |